Clinical and biological predictors of outcome following relapse of CML post-allo-SCT

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Bone Marrow Transplantation

• Publication date

  2015-02-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2014.249PMID 25387087PMCID PMC4318796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.

  2013cited by this paper
• CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML

  2013cited by this paper
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

  2011cited by this paper
• PROGNOSTIC FACTORS FOR OUTCOMES IN ALLOGENEIC TRANSPLANTATION FOR ADVANCED PHASES OF CHRONIC MYELOID LEUKEMIA IN THE IMATINIB ERA: A CIBMTR ANALYSIS

  2011cited by this paper
• Three decades of transplantation for chronic myeloid leukemia: what have we learned?

  2011cited by this paper
• Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.

  2011cited by this paper
• In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

  2010cited by this paper
• Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.

  2010cited by this paper
• The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

  2009cited by this paper
• The blast phase of chronic myeloid leukaemia.

  2009cited by this paper
• Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

  2008cited by this paper
• Understanding and harnessing the graft‐versus‐leukaemia effect

  2008cited by this paper
• Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

  2006cited by this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cited by this paper
• Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

  2006cited by this paper
• Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

  2006cited by this paper
• Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.

  2006cited by this paper
• Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease

  2005cited by this paper
• Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

  2005cited by this paper
• Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment

  2004cited by this paper
• Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

  2003cited by this paper
• Chronic myeloid leukemia--advances in biology and new approaches to treatment.

  2003cited by this paper
• Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation

  2003cited by this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.

  2003cited by this paper
• Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

  2002cited by this paper
• Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation

  1999cited by this paper
• Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR

  1998cited by this paper
• 10 Graft-versus-leukaemia

  1997cited by this paper
• Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.

  1995cited by this paper
• Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.

  1994cited by this paper
• Bone marrow transplantation for patients with chronic myeloid leukemia.

  1986cited by this paper
• ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA

  1984cited by this paper
• Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation.

  1982cited by this paper

• The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study -

  2023cites this paper
• Side Effects and Sequelae of Treatment for Chronic Myeloid Leukemia in Childhood and Adolescence

  2020cites this paper
• Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

  2019cites this paper
• Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies

  2019cites this paper
• Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

  2018cites this paper
• Chronic myeloid leukemia: reminiscences and dreams

  2016cites this paper
• VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells

  2016cites this paper
• VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells

  2016cites this paper